COVID-19 in Russia: Evolution of Views on the Pandemic. Report II
- Authors: Starodubov V.I.1, Beregovykh V.V.2, Akimkin V.G.3, Semenenko T.A.4, Ugleva S.V.3, Avdeev S.N.2, Zykov K.A.5,6, Trofimova T.N.7, Pogosova N.V.8, Perekhodov S.N.6,9, Kuzin S.N.3, Yacyshina S.B.3, Petrov V.V.3, Khafizov K.F.3, Dubodelov D.V.3, Gasanov G.A.3, Svanadze N.K.3, Cherkashina A.S.3, Sinitsyn E.A.5,6, Rvacheva A.V.6, Sergeeva N.V.9, Polosova T.A.6, Zykova A.A.6, Zelenin D.A.6,10, Gorbenko M.Y.10, Rodyukova I.S.10,11, Chaus N.I.10,12, Snitsar A.V.10
-
Affiliations:
- Russian Research Institute of Health
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
- National Research Center of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya
- Pulmonology Scientific Research Institute under Federal Medical and Biological Agency of Russian Federation
- А.I. Yevdokimov Moscow State University of Medicine and Dentistry
- Pavlov First St. Petersburg State Medical University
- National Medical Research Center of Cardiology named after Academician E.I. Chazov
- Professor G.A. Zakharyin Tuberculosis Clinical Hospital No. 3
- City Clinical Hospital named after V.P. Demihov
- Pirogov Russian National Research Medical University (Pirogov Medical University)
- Russian Medical Academy of Continuous Professional Education
- Issue: Vol 77, No 4 (2022)
- Pages: 291-306
- Section: EPIDEMIOLOGY: CURRENT ISSUES
- URL: https://vestnikramn.spr-journal.ru/jour/article/view/2122
- DOI: https://doi.org/10.15690/vramn2122
Cite item
Abstract
Over the two years of the novel coronavirus infection (COVID-19) pandemic, there has been an evolution of views in various fields of medicine, which has led to a powerful development of scientific research in the field of epidemiology, clinic, diagnosis and therapy of COVID-19. This article discusses the evolution of views and approaches to the study of the clinic and therapy of COVID-19. The symptoms and aggravation of the course of cardiovascular diseases with COVID-19 have been established. The main strategy for organizing surgical care for patients with COVID-19 is indicated. The main criteria for the treatment of COVID-19, the need to prescribe SGCS on an individual basis, and the need to search for new methods of anti-inflammatory therapy for COVID-19, one of which may be the use of alkylating drugs in ultra-low doses, are described.
Keywords
Full Text

About the authors
Vladimir I. Starodubov
Russian Research Institute of Health
Email: starodubov@mednet.ru
ORCID iD: 0000-0002-3625-4278
SPIN-code: 7223-9834
MD, PhD, Professor, Academician of the RAS
Russian Federation, MoscowValery V. Beregovykh
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: beregovykh@ramn.ru
ORCID iD: 0000-0002-0210-4570
SPIN-code: 5940-7554
PhD in Technical Sciences, Professor, Academician of the RAS
Russian Federation, MoscowVasily G. Akimkin
Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
Email: vgakimkin@yandex.ru
ORCID iD: 0000-0003-4228-9044
SPIN-code: 4038-7455
MD, PhD, Professor, Academician of the RAS
Russian Federation, 3a, Novogireevskaya str., 111123, MoscowTatiana A. Semenenko
National Research Center of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya
Email: meddy@inbox.ru
ORCID iD: 0000-0002-6686-9011
SPIN-code: 8375-2270
MD, PhD, Professor
Russian Federation, MoscowSvetlana V. Ugleva
Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
Author for correspondence.
Email: uglevas@bk.ru
ORCID iD: 0000-0002-1322-0155
SPIN-code: 8840-5814
MD, PhD, Associate Professor
Russian Federation, 3a, Novogireevskaya str., 111123, MoscowSergey N. Avdeev
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: serg_avdeev@list.ru
ORCID iD: 0000-0002-5999-2150
SPIN-code: 1645-5524
MD, PhD, Professor, Corresponding Member of the RAS
Russian Federation, MoscowKirill A. Zykov
Pulmonology Scientific Research Institute under Federal Medical and Biological Agency of Russian Federation; А.I. Yevdokimov Moscow State University of Medicine and Dentistry
Email: kiriliaz@inbox.ru
ORCID iD: 0000-0003-3385-2632
SPIN-code: 6269-7990
MD, PhD, Professor of the RAS
Russian Federation, Moscow; MoscowTatiana N. Trofimova
Pavlov First St. Petersburg State Medical University
Email: ttrofimova@sogaz-clinic.ru
ORCID iD: 0000-0003-4871-2341
SPIN-code: 9733-2755
MD, PhD, Professor
Russian Federation, St. PetersburgNana V. Pogosova
National Medical Research Center of Cardiology named after Academician E.I. Chazov
Email: nanapogosova@gmail.com
ORCID iD: 0000-0002-4165-804X
SPIN-code: 4168-6400
MD, PhD, Professor
Russian Federation, MoscowSergey N. Perekhodov
А.I. Yevdokimov Moscow State University of Medicine and Dentistry; Professor G.A. Zakharyin Tuberculosis Clinical Hospital No. 3
Email: persenmd@mail.ru
ORCID iD: 0000-0001-7166-0290
SPIN-code: 8770-6877
MD, PhD, Professor
Russian Federation, Moscow; MoscowStanislav N. Kuzin
Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
Email: kuzin@cmd.su
ORCID iD: 0000-0002-0616-9777
SPIN-code: 1372-7623
MD, PhD, Professor
Russian Federation, 3a, Novogireevskaya str., 111123, MoscowSvetlana B. Yacyshina
Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
Email: svetlana.yatsyshina@pcr.ms
ORCID iD: 0000-0003-4737-941X
SPIN-code: 7156-2948
PhD in Biology, Senior Research Associate
Russian Federation, 3a, Novogireevskaya str., 111123, MoscowVadim V. Petrov
Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
Email: petrov@pcr.ms
ORCID iD: 0000-0002-3503-2366
SPIN-code: 9852-8292
head of the scientific group for the development of new molecular biological technologies
Russian Federation, 3a, Novogireevskaya str., 111123, MoscowKamil F. Khafizov
Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
Email: khafizov@cmd.su
ORCID iD: 0000-0001-5524-0296
SPIN-code: 9082-5749
PhD in Biology
Russian Federation, 3a, Novogireevskaya str., 111123, MoscowDmitry V. Dubodelov
Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
Email: dubodelov@cmd.su
ORCID iD: 0000-0003-3093-5731
SPIN-code: 4860-7909
MD, PhD
Russian Federation, 3a, Novogireevskaya str., 111123, MoscowGasan A. Gasanov
Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
Email: gasanovgt500@gmail.com
ORCID iD: 0000-0002-0121-521X
SPIN-code: 9726-9380
Russian Federation, 3a, Novogireevskaya str., 111123, Moscow
Nino Kh. Svanadze
Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
Email: svanadze@cmd.su
ORCID iD: 0000-0001-7524-3080
MD
Russian Federation, 3a, Novogireevskaya str., 111123, MoscowAnna S. Cherkashina
Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
Email: cherkashina@pcr.ms
ORCID iD: 0000-0001-7970-7495
SPIN-code: 7854-7358
PhD in Chemistry
Russian Federation, 3a, Novogireevskaya str., 111123, MoscowEvgeny A. Sinitsyn
Pulmonology Scientific Research Institute under Federal Medical and Biological Agency of Russian Federation; А.I. Yevdokimov Moscow State University of Medicine and Dentistry
Email: sinymlad@list.ru
ORCID iD: 0000-0002-8813-5932
SPIN-code: 3156-7024
Chief Physician of the Medical Center
Russian Federation, Moscow; MoscowAnna V. Rvacheva
А.I. Yevdokimov Moscow State University of Medicine and Dentistry
Email: arvatcheva@mail.ru
ORCID iD: 0000-0001-9277-2291
SPIN-code: 5267-9598
MD, PhD
Russian Federation, MoscowNatal'ya V. Sergeeva
Professor G.A. Zakharyin Tuberculosis Clinical Hospital No. 3
Email: Tkb_3@mail.ru
assistant of the Department of Infectious Diseases
Russian Federation, MoscowTatiana A. Polosova
А.I. Yevdokimov Moscow State University of Medicine and Dentistry
Email: uglevas@bk.ru
MD, PhD, Associate Professor
Russian Federation, MoscowAlexandra A. Zykova
А.I. Yevdokimov Moscow State University of Medicine and Dentistry
Email: zykova.aal@medsigroup.ru
ORCID iD: 0000-0001-9577-4815
MD, PhD
Russian Federation, MoscowDmitrii A. Zelenin
А.I. Yevdokimov Moscow State University of Medicine and Dentistry; City Clinical Hospital named after V.P. Demihov
Email: zelenin@68gkb.ru
ORCID iD: 0000-0001-6622-4734
SPIN-code: 9418-3070
MD, PhD
Russian Federation, Moscow; MoscowMihail Yu. Gorbenko
City Clinical Hospital named after V.P. Demihov
Email: gorbenko@pochta.ru
ORCID iD: 0000-0003-4678-5459
SPIN-code: 8064-1419
MD, PhD
Russian Federation, MoscowIrina S. Rodyukova
City Clinical Hospital named after V.P. Demihov; Pirogov Russian National Research Medical University (Pirogov Medical University)
Email: irina.rodyukova@gmail.com
ORCID iD: 0000-0001-9548-6426
SPIN-code: 8161-4082
MD, PhD, Associate Professor
Russian Federation, Moscow; MoscowNikolay I. Chaus
City Clinical Hospital named after V.P. Demihov; Russian Medical Academy of Continuous Professional Education
Email: nikchaus@yandex.ru
ORCID iD: 0000-0001-5891-3417
MD, PhD, Associate Professor
Russian Federation, Moscow; MoscowArtem V. Snitsar
City Clinical Hospital named after V.P. Demihov
Email: snitsar@68gkb.ru
ORCID iD: 0000-0001-6053-4651
SPIN-code: 3059-5317
MD
Russian Federation, MoscowReferences
- Wuhan Municipal Health Commission. Report of clustering pneumonia of unknown etiology in Wuhan City. Wuhan, China: Wuhan Municipal Health Commission. Available from: http://wjw.wuhan.gov.cn/ front/web/showDetail/2019123108989 (In Chin.)
- COVID-19 Research and Innovation. Powering the world’s pandemic response – now and in the future. Available from: https://cdn.who.int/media/docs/default-source/blue-print/achievement-report-_grif_web_finalversion15.pdf?sfvrsn=39052c73_9&download=true
- COVID-19, MERS & SARS/NIH: National Institute of Allergy and Infectious Diseases. (n.d.). Retrieved September 6, 2020. Available from: https://www.niaid.nih.gov/diseases-conditions/covid-19
- Коронавирус. Available from: https://coronavirus-monitor.info/
- Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–2059. doi: https://doi.org/10.1001/jama.2020.6775
- Xu J, Xiao W, Liang X, et al. A meta-analysis on the risk factors adjusted association between cardiovascular disease and COVID-19 severity. BMC Public Health. 2021;21(1):1533. doi: https://doi.org/10.1186/s12889-021-11051-w
- Tian W, Jiang W, Yao J. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2020;92(10):1875–1883. doi: https://doi.org/10.1002/jmv.26050
- Бойцов С.А., Погосова Н.В., Палеев Ф.Н., и др. Клиническая картина и факторы, ассоциированные с неблагоприятными исходами у госпитализированных пациентов с новой коронавирусной инфекцией COVID-19 // Кардиология. — 2021. — Т. 61. — № 2. — С. 4–14. [Boytsov SA, Pogosova NV, Paleev FN, et al. Clinical Characteristics and Factors Associated with Poor Outcomes in Hospitalized Patients with Novel Coronavirus Infection COVID-19. Kardiologiia. 2021;61(2):4–14. (In Russ.)] doi: https://doi.org/10.18087/cardio.2021.2.n1532
- Шляхто Е.В., Конради А.О., Арутюнов Г.П., и др. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19 // Российский кардиологический журнал. — 2020. — Т. 25. — № 3. — С. 3801. [Shlyakho EV, Konradi AO, Arutyunov GP, et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):3801. (In Russ.)] doi: https://doi.org/10.15829/1560-4071-2020-3-3801
- Banerjee A, Chen S, Pasea L, et al. Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic. Eur J Prev Cardiol. 2021;28(14):1599–1609. doi: https://doi.org/10.1093/eurjpc/zwaa155
- Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study. BMJ. 2021;372:n693. doi: https://doi.org/10.1136/bmj.n693
- Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583–590. doi: https://doi.org/10.1038/s41591-022-01689-3
- Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351(25):2611–2618. doi: https://doi.org/10.1056/NEJMoa041747
- Libby P, Luscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41(32):3038–3044. doi: https://doi.org/10.1093/eurheartj/ehaa623
- Бурячковская Л.И., Мелькумянц А.М., Ломакин Н.В., и др. Повреждение сосудистого эндотелия и эритроцитов у больных COVID-19 // Consilium Medicum. — 2021. — Т. 23. — № 6. — С. 469–476. [Buryachkovskaya LI, Melkumyants AM, Lomakin NV, et al. Injury of vascular endothelium and erythrocytes in COVID-19 patients. Consilium Medicum. 2021;23(6):469–476. (In Russ.)] doi: https://doi.org/10.26442/20751753.2021.6.200939
- Ahmed H, Patel K, Greenwood DC, et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome coronavirus (MERS) outbreaks after hospitalization or ICU admission: a systematic review and meta-analysis. J Rehabil Med. 2020;52(5):jrm00063. doi: https://doi.org/10.2340/16501977-2694
- Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259–264. doi: https://doi.org/10.1038/s41586-021-03553-9
- Арутюнов Г.П., Тарловская Е.И., Арутюнов А.Г., и др. Международный регистр «Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2 (aктив SARS-CoV-2)»: анализ 1000 пациентов // Российский кардиологический журнал. — 2020. — Т. 25. — № 11. — С. 4165. [Arutyunov GP, Tarlovskaya EI, Arutyunov AG. International register “Dynamics analysis of comorbidities in SARS-CoV-2 survivors” (AKTIV SARS-CoV-2): analysis of 1,000 patients. Russian Journal of Cardiology. 2020;25(11):4165. (In Russ.)] doi: https://doi.org/10.15829/1560-4071-2020-4165
- Погосова Н.В., Палеев Ф.Н., Аушева А.К., и др. Последствия COVID-19 на отдаленном этапе после госпитализации // Рациональная фармакотерапия в кардиологии. — 2022. — Т. 18. — № 2. — С. 118–126. [Pogosova NV, Paleev FN, Ausheva AK, et al. Sequelae of COVID-19 at long-term follow-up after hospitalization. Rational Pharmacotherapy in Cardiology. 2022;18(2):118–126. (In Russ.)] doi: https://doi.org/10.20996/1819-6446-2022-04-03
- Ti LK, Ang LS, Foong TW, et al. What we do when a COVID-19 patient needs an operation: operating room preparation and guidance. Can J Anaesth. 2020;67(6):756–758. doi: https://doi.org/10.1007/s12630-020-01617-4
- Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology. 2020;158(6):1518–1519. doi: https://doi.org/10.1053/j.gastro.2020.02.054
- Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323(14):1406–1407. doi: https://doi.org/10.1001/jama.2020.2565
- Kampf G, Todt D, Pfaender S, et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246–251. doi: https://doi.org/10.1016/j.jhin.2020.01.022
- Письмо Роспотребнадзора от 11.04.2020 № 02/6673-2020-32 «О направлении рекомендаций по применению СИЗ для различных категорий граждан при рисках инфицирования COVID-19» (вместе с МР 3.1/3.5.0172/1-20. 3.1. Профилактика инфекционных болезней. 3.5. Дезинфектология. Рекомендации по применению средств индивидуальной защиты (в том числе многоразового использования) для различных категорий граждан при рисках инфицирования COVID-19. Методические рекомендации).
- Sartelli M, Chichom-Mefire A, Labricciosa FM, et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg. 2017;12:29. doi: https://doi.org/10.1186/s13017-017-0141-6
- Di Saverio S, Podda M, De Simone B, et al. Diagnosis and treatment of acute appendicitis: 2020 update of the WSES Jerusalem guidelines. World J Emerg Surg. 2020;15(1):27. doi: https://doi.org/10.1186/s13017-020-00306-3
- De Simone B, Chouillard E, Di Saverio S, et al. Emergency surgery during the COVID-19 pandemic: what you need to know for practice. Ann R Coll Surg Engl. 2020;102(5):323–332. doi: https://doi.org/10.1308/rcsann.2020.0097
- Ansaloni L, Pisano M, Coccolini F, et al. 2016 WSES guidelines on acute calculous cholecystitis. World J Emerg Surg. 2016;11:25. doi: https://doi.org/10.1186/s13017-016-0082-5
- Loozen CS, van Santvoort HC, van Duijvendijk P, et al. Laparoscopic cholecystectomy versus percutaneous catheter drainage for acute cholecystitis in high risk patients (CHOCOLATE): multicentre randomised clinical trial. BMJ. 2018;363:k3965. doi: https://doi.org/10.1136/bmj.k3965
- Щеголев А.А. (ред.). Желчекаменная болезнь: учебно-метод. пособие. — М.: РНИМУ, 2015. — 35 с. [Shchegolev AA (red.). Zhelchekamennaya bolezn': uchebno-metod. posobie. Moscow: RNIMU; 2015. 35 s. (In Russ.)]
- Pisano M, Zorcolo L, Merli C, et al. 2017 WSES guidelines on colon and rectal cancer emergencies: obstruction and perforation. World J Emerg Surg. 2018;13:36. doi: https://doi.org/10.1186/s13017-018-0192-3
- Ten Broek RP, Krielen P, Di Saverio S, et al. Bologna guidelines for diagnosis and management of adhesive small bowel obstruction (ASBO): 2017 update of the evidence-based guidelines from the World Society of Emergency Surgery ASBO working group. World J Emerg Surg. 2018;13:24. doi: https://doi.org/10.1186/s13017-018-0185-2
- Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–2040. doi: https://doi.org/10.1182/blood.2020006000
- Bahloul M, Chaari A, Ben Algia N, et al. Pulmonary embolism in intensive care unit “literature review”. Trends Anaesth Crit. 2012;2(1):25–29. doi: https://doi.org/10.1016/j.tacc.2011.11.005
- Reyes Valdivia A, Aracil Sanus E, Duque Santos Á, et al. Adapting vascular surgery practice to the current COVID-19 era at a tertiary academic center in Madrid. Ann Vasc Surg. 2020;67:1–5. doi: https://doi.org/10.1016/j.avsg.2020.06.001
- Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for Treatment of Patients with Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin Infect Dis. 2021;73(3):531–534. doi: https://doi.org/10.1093/cid/ciaa1176
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med. 2020;383:1813–1826. doi: https://doi.org/10.1056/NEJMoa2007764
- Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients. N Engl J Med. 2022;386(6):509–520. doi: https://doi.org/10.1056/NEJMoa2116044
- Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19. N Engl J Med. 2022;386(15):1397–1408. doi: https://doi.org/10.1056/NEJMoa2118542
- Bruzzesi E, Ranzenigo M, Castagna A, et al. Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection. New Microbiol. 2021;44(3):135–144.
- RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with COVID-19. N Engl J Med. 2021;384(8):693–704. doi: https://doi.org/10.1056/NEJMoa2021436
- WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Sterne JAC, Murthy S, Diaz JV, et al. Association Between Administration of Systemic Corticosteroids And Mortality Among Critically Ill Patients with COVID-19: A Meta-Analysis. JAMA. 2020;324(13):1330–1341. doi: https://doi.org/10.1001/jama.2020.17023
- REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19. N Engl J Med. 2021;384(16):1491–1502. doi: https://doi.org/10.1056/NEJMoa2100433
- RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–1645. doi: https://doi.org/10.1016/S0140-6736(21)00676-0
- ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators; Lawler PR, Goligher EC, Berger JS, et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with COVID-19. N Engl J Med. 2021;385(9):790–802. doi: https://doi.org/10.1056/NEJMoa2105911
- Баутин А.Е., Авдеев С.Н., Сейлиев А.А., и др. Ингаляционная терапия сурфактантом в комплексном лечении тяжелой формы COVID-19-пневмонии // Туберкулез и болезни легких. — 2020. — Т. 98. — № 9. — С. 6–12. [Bautin АE, Аvdeev SN, Seyliev АА, et al. А. Inhalation surfactant therapy in the integrated treatment of severe COVID-19 pneumonia. Tuberculosis and Lung Diseases. 2020;98(9):6–12. (In Russ.)] doi: http://doi.org/10.21292/2075-1230-2020-98-9-6-12
- Avdeev SN, Trushenko NV, Chikina SY, et al. Beneficial effects of inhaled surfactant in patients with COVID-19-associated acute respiratory distress syndrome. Respir Med. 2021;185:106489. doi: https://doi.org/10.1016/j.rmed.2021.106489
- Tsareva NA, Avdeev SN, Kosanovic D, et al. Inhaled iloprost improves gas exchange in patients with COVID-19 and acute respiratory distress syndrome. Crit Care. 2021;25(1):258. doi: https://doi.org/10.1186/s13054-021-03690-7
- Авдеев С.Н., Царева Н.А., Мержоева З.М., и др. Практические рекомендации по кислородотерапии и респираторной поддержке пациентов с COVID-19 на дореанимационном этапе // Пульмонология. — 2020. — Т. 30. — № 2. — С. 151–163. [Avdeev SN, Tsareva NA, Merzhoeva ZM, et al. Practical guidelines for oxygen therapy and respiratory support for patients with COVID-19 in the pre-life support. Pulmonology. 2020;30(2):151–163 (In Russ.)] doi: https://doi.org/10.18093/0869-0189-2020-30-2-151-163
- Faculty of Intensive Care Medicine, Intensive Care Society, Association of Anaesthetists and Royal College of Anaesthetists. Critical care preparation and management in the COVID-19 pandemic. Available at: https://www.icmanaesthesiacovid-19.org/critical-care-preparation-and-management-in-the-covid-19-pandemic
- Oranger M, Gonzalez-Bermejo J, Dacosta-Noble P, et al. Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: a two-period retrospective case-control study. Eur Respir J. 2020;56(2):2001692. doi: https://doi.org/10.1183/13993003.01692-2020
- Bellani G, Grasselli G, Cecconi M, et al. Noninvasive Ventilatory Support of COVID-19 Patients Outside the Intensive Care Units. Ann Am Thorac Soc. 2021;18(6):1020–1026. doi: https://doi.org/10.1513/AnnalsATS.202008-1080OC
- Avdeev S, Yaroshetskiy A, Tsareva N, et al. Noninvasive ventilation for acute hypoxemic respiratory failure in patients with COVID-19. Am J Emerg Med. 2021;39:154–157. doi: https://doi.org/10.1016/j.ajem.2020.09.075
- Grieco DL, Menga LS, Cesarano M, et al. Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on days free of respiratory support in patients with COVID-19 and moderate to severe hypoxemic respiratory failure: the HENIVOT randomized clinical trial. JAMA. 2021;325(17):1731–1743. doi: https://doi.org/10.1001/jama.2021.4682
- Perkins GD, Ji C, Connolly BA, et al. Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients with Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial. JAMA. 2022;327(6):546–558. doi: https://doi.org/10.1001/jama.2022.0028
- Авдеев С.Н. Неинвазивная вентиляция легких при новой коронавирусной инфекции COVID-19 // Пульмонология. — 2020. — Т. 30. — № 5. — С. 679–687. [Avdeev SN. Non-invasive ventilation in patients with novel coronavirus infection COVID-19. Pulmonologiya. 2020;30(5):679-687.] (In Russ.) doi: https://doi.org/10.18093/0869-0189-2020-30-5-679-687
- Pelosi P, Tubiolo D, Mascheroni D, et al. Effects of the prone position on respiratory mechanics and gas exchange during acute lung injury. Am J Respir Crit Care Med. 1998;157(2):387–393. doi: https://doi.org/10.1164/ajrccm.157.2.97-04023
- Ehrmann S, Li J, Ibarra-Estrada M, et al. Awake Prone Positioning Meta-Trial Group. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respir Med. 2021;9(12):1387–1395. doi: https://doi.org/10.1016/S2213-2600(21)00356-8
- Avdeev SN, Nekludova GV, Trushenko NV, et al. Lung ultrasound can predict response to the prone position in awake non-intubated patients with COVID-19 associated acute respiratory distress syndrome. Crit Care. 2021;25(1):35. doi: https://doi.org/10.1186/s13054-021-03472-1
- WHO Coronavirus (COVID-19) Dashboard. Available from: https://covid19.who.int (accessed: 11.05.2022).
- Отчет о текущей ситуации по борьбе с коронавирусом. Коммуникационный центр Правительства Российской Федерации. 11.05.2022. [Otchet o tekushei situacii po bor’be s koronavirusom. Available from: Kommunikacionnii centr Pravitel’stva Rossiiskoi Federacii. 11.05.2022. (In Russ.)] Available from: https://стопкоронавирус.рф
- Оковитый С.В. Клиническая фармакология иммунодепрессантов // Обзоры по клинической фармакологии и лекарственной терапии. — 2003. — Т. 2. — № 2. — С. 2–34. [Okovityj SV. Klinicheskaya farmakologiya immunodepressantov. Obzory po klinicheskoj farmakologii i lekarstvennoj terapii. 2003;2(2):2–34. (In Russ.)]
- COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet. 2022;399(10334):1513–1536. doi: https://doi.org/10.1016/S0140-6736(21)02796-3
- Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451–1454. doi: https://doi.org/10.1038/s41418-020-0530-3
- Козлов В.А., Савченко А.А., Кудрявцев И.В., и др. Клиническая иммунология. — Красноярск: Поликор, 2020. — 386 с. [Kozlov VA, Savchenko AA, Kudryavcev IV, i dr. Klinicheskaya immunologiya. Krasnoyarsk: Polikor; 2020. 386 s. (In Russ.)]
- Wang J, Yang W, Chen P, et al. The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis. PLoS One. 2021;16(4):e0249481. doi: https://doi.org/10.1371/journal.pone.0249481
- Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 15. 22.02.2022. Available from: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/ВМР_COVID-19_V15.pdf
- Snow TAC, Saleem N, Ambler G, et al. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials. Intensive Care Med. 2021;47(6):641–652. doi: https://doi.org/10.1007/s00134-021-06416-z
- Selvaraj V, Khan MS, Bavishi C, et al. Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials. Lung. 2021;199(3):239–248. doi: https://doi.org/10.1007/s00408-021-00451-9
- RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–1645. doi: https://doi.org/10.1016/S0140-6736(21)00676-0
- Patoulias D, Doumas M, et al. Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clin Rheumatol. 2021;40(11):4671–4674. doi: https://doi.org/10.1007/s10067-021-05884-4
- Ma S, Xu C, Liu Sh, et al. Efficacy and safety of systematic corticosteroids among severe COVID‐19 patients: a systematic review and meta‐analysis of randomized controlled trials. Signal Transduct Target Ther. 2021;6(1):83. doi: https://doi.org/10.1038/s41392-021-00521-7
- RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693–704. doi: https://doi.org/10.1056/NEJMoa2021436
- The COVID STEROID 2 Trial Group; Munch MW, Myatra SN, Vijayaraghavan BKT, et al. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. JAMA. 2021;326(18):1807–1817. doi: https://doi.org/10.1001/jama.2021.18295
- Jamaati H, Hashemian SMR, Farzanegan B, et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. Eur J Pharmacol. (2021);897:173947. doi: https://doi.org/10.1016/j.ejphar.2021.173947
- Oganesyan A., Zykov K, Surovoy Y, et al. Target Groups for a Short Dexamethasone Course among Critically Ill COVID-19 Patients. Crit Care Res Pract. 2021;2021:5557302. doi: https://doi.org/10.1155/2021/5557302
- Jung C, Wernly B, Fjølner J, et al. and the COVIP study group. Steroid use in elderly critically ill COVID-19 patients. Eur Respir J. 2021;58(4):2100979. doi: https://doi.org/10.1183/13993003.00979-2021
- Duarte MBO, Leal F, et al. Outcomes of COVID-19 Patients under Cytotoxic Cancer Chemotherapy in Brazil. Cancers (Basel). 2020;12(12):3490. doi: https://doi.org/10.3390/cancers12123490
- Синицын Е.А., Зыкова А.А., Шамин Р.В., и др. Эффективность и безопасность применения ингаляций ультранизких доз мелфалана в лечении госпитализированных пациентов с COVID-19 // Acta Biomedica Scientifica. — 2022. — Т. 7. — № 2. — С. 12–23. [Sinitsyn EA, Zykova AA, Shamin RV, et al. Efficacy and safety of ultra-low dose inhaled melphalan in the treatment of hospitalized patients with COVID-19. Acta Biomedica Scientifica. 2022;7(2):12–23. (In Russ.)] doi: https://doi.org/10.29413/ABS.2022-7.2.2
Supplementary files
